Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections

Importance Ritonavir-boosted nirmatrelvir and molnupiravir are currently used in the US and in other countries to treat nonhospitalized patients who have mild-to-moderate COVID-19 and who are at high risk for progression to severe disease. The associations of these 2 oral antiviral drugs with hospit...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	JAMA network open 2023-09, Vol.6 (9), p.e2335077-e2335077
Hauptverfasser:	Lin, Dan-Yu, Abi Fadel, Francois, Huang, Shuaiqi, Milinovich, Alex T., Sacha, Gretchen L., Bartley, Patricia, Duggal, Abhijit, Wang, Xiaofeng
Format:	Artikel
Sprache:	eng
Schlagworte:	COVID-19 vaccines Ethnicity Hospitalization Immunization Infections Infectious Diseases Online Only Original Investigation Severe acute respiratory syndrome coronavirus 2
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!